2021 Fiscal Year Final Research Report
Verification of the therapeutic effect improvement of BNCT brought about by MID-HSA administered with CED
Project/Area Number |
20K17945
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 56010:Neurosurgery-related
|
Research Institution | Osaka Medical and Pharmaceutical University |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2022-03-31
|
Keywords | 脳腫瘍 / brain tumor / BNCT / CED / boron / MID / Albumin |
Outline of Final Research Achievements |
Intravenous administration of MID-AC, a newly developed boron compound, to brain tumor model rats has the property that boron can be sufficiently taken up into the tumor and stays in the tumor for a long period of time. Boron neutron capture therapy (BNCT) was performed on brain tumor model rats using this drug, and a significant prolongation of survival was observed compared to the untreated group, and the therapeutic effect equivalent to that of the conventional therapeutic drug BPA was achieved.
|
Free Research Field |
脳腫瘍
|
Academic Significance and Societal Importance of the Research Achievements |
上記の研究結果から長時間の照射や多方向照射が必要な深部腫瘍や多発病変においても安定した治療効果を供給できる可能性が示された。BNCTは悪性脳腫瘍を含めた難治性腫瘍に対し期待されている新たな治療である。今回ホウ素クラスターと合成したヒト血清アルブミンはがん集積性タンパク質であり、これを利用し抗がん剤と結合させた薬剤開発が盛んに行われており、本薬剤が脳腫瘍以外の悪性腫瘍にも治療効果を示す可能性があり学術的意義は高いと考える。またBNCTにより悪性脳腫瘍の治療成績は向上しているが、未だ十分なものとは言えずさらなる治療成績の向上は社会的意義の非常に高いものと考える。
|